Alanine aminotransferase predicts coronary heart disease events: A 10-year follow-up of the Hoorn Study

Atherosclerosis

Volumn 191, Issue 2, 2007, Pages 391-396

  Schindhelm, Roger K ^a   Dekker, Jacqueline M ^b   Nijpels, Giel ^a,b   Bouter, Lex M ^b   Stehouwer, Coen D A ^c   Heine, Robert J ^a,b   Diamant, Michaela ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Alanine aminotransferase; Coronary heart disease events; Epidemiology

Indexed keywords

ALANINE AMINOTRANSFERASE;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CAUCASIAN; COHORT ANALYSIS; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL;

AGED; ALANINE TRANSAMINASE; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CORONARY DISEASE; DIABETES MELLITUS, TYPE 2; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; MALE; MIDDLE AGED; NETHERLANDS; POPULATION SURVEILLANCE; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SURVIVAL ANALYSIS; TIME FACTORS;

EID: 33947169979     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2006.04.006     Document Type: Article

References (28)

1. Gupte P., Amarapurkar D., Agal S., et al. Non-alcoholic steatohepatitis in type 2 diabetes mellitus. J Gastroenterol Hepatol 19 8 (2004) 854-858
2. Younossi Z.M., Gramlich T., Matteoni C.A., et al. Nonalcoholic fatty liver disease in patients with type 2 diabetes. Clin Gastroenterol Hepatol 2 3 (2004) 262-265
3. Cortez-Pinto H., Camilo M.E., Baptista A., et al. Non-alcoholic fatty liver: another feature of the metabolic syndrome?. Clin Nutr 18 6 (1999) 353-358
4. Knobler H., Schattner A., Zhornicki T., et al. Fatty liver - an additional and treatable feature of the insulin resistance syndrome. QJM 92 (1999) 73-79
5. Westerbacka J., Corner A., Tiikkainen M., et al. Women and men have similar amounts of liver and intra-abdominal fat, despite more subcutaneous fat in women: implications for sex differences in markers of cardiovascular risk. Diabetologia 47 (2004) 1360-1369
6. Sattar N., Scherbakova O., Ford I., et al. Elevated alanine aminotransferase predicts new-onset type 2 diabetes independently of classical risk factors, metabolic syndrome, and C-reactive protein in the west of Scotland coronary prevention study. Diabetes 53 (2004) 2855-2860
7. Vozarova B., Stefan N., Lindsay R.S., et al. High alanine aminotransferase is associated with decreased hepatic insulin sensitivity and predicts the development of type 2 diabetes. Diabetes 51 (2002) 1889-1895
8. Dekker J.M., Girman C., Rhodes T., et al. Metabolic syndrome and 10-year cardiovascular disease risk in the Hoorn Study. Circulation 112 (2005) 666-673
9. Schindhelm R.K., Diamant M., Bakker S.J.L., et al. Liver alanine aminotransferase, insulin resistance and endothelial dysfunction in normotriglyceridaemic subjects with type 2 diabetes mellitus. Eur J Clin Invest 35 (2005) 369-374
10. Brea A., Mosquera D., Martin E., et al. Nonalcoholic fatty liver disease is associated with carotid atherosclerosis: a case-control study. Arterioscler Thromb Vasc Biol 25 (2005) 1045-1050
11. Mooy J.M., Grootenhuis P.A., de Vries H., et al. Prevalence and determinants of glucose intolerance in a Dutch caucasian population. The Hoorn Study. Diabetes Care 18 (1995) 1270-1273
12. Bergmeyer H.U., Horder M., and Rej R. International Federation of Clinical Chemistry (IFCC) Scientific Committee, Analytical Section: approved recommendation (1985) on IFCC methods for the measurement of catalytic concentration of enzymes. Part 3. IFCC method for alanine aminotransferase (l-alanine: 2-oxoglutarate aminotransferase, EC 2.6.1.2). J Clin Chem Clin Biochem 24 (1986) 481-495
13. Kaplan M.M. Alanine aminotransferase levels: what's normal?. Ann Intern Med 137 (2002) 49-51
14. Ratziu V., Imbert-Bismut F., Messous D., and Poynard T. The elusiveness of "normal" ALT in fatty liver. Hepatology 39 (2004) 1172
15. Matthews D.R., Hosker J.P., Rudenski A.S., et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28 (1985) 412-419
16. Grootenhuis P.A., Westenbrink S., Sie C.M., et al. A semiquantitative food frequency questionnaire for use in epidemiologic research among the elderly: validation by comparison with dietary history. J Clin Epidemiol 48 (1995) 859-868
17. Kannel W.B., Plehn J.F., and Cupples L.A. Cardiac failure and sudden death in the Framingham Study. Am Heart J 115 (1988) 869-875
18. Arndt V., Brenner H., Rothenbacher D., et al. Elevated liver enzyme activity in construction workers: prevalence and impact on early retirement and all-cause mortality. Int Arch Occup Environ Health 71 (1998) 405-412
19. Bruckert E., Giral P., Ratziu V., et al. A constellation of cardiovascular risk factors is associated with hepatic enzyme elevation in hyperlipidemic patients. Metabolism 51 (2002) 1071-1076
20. Targher G., Bertolini L., Padovani R., et al. Relation of nonalcoholic hepatic steatosis to early carotid atherosclerosis in healthy men: role of visceral fat accumulation. Diabetes Care 27 (2004) 2498-2500
21. Hunt K.J., Resendez R.G., Williams K., et al. National Cholesterol Education Program versus World Health Organization metabolic syndrome in relation to all-cause and cardiovascular mortality in the San Antonio Heart Study. Circulation 110 (2004) 1251-1257
22. Kern P.A., Ranganathan S., Li C., et al. Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am J Physiol Endocrinol Metab 280 (2001) E745-E751
23. Kerner A., Avizohar O., Sella R., et al. Association between elevated liver enzymes and C-reactive protein. possible hepatic contribution to systemic inflammation in the metabolic syndrome. Arterioscler Thromb Vasc Biol (2004) 01
24. Sakkinen P., Abbott R.D., Curb J.D., et al. C-reactive protein and myocardial infarction. J Clin Epidemiol 55 (2002) 445-451
25. Ridker P.M., Hennekens C.H., Buring J.E., et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 342 (2000) 836-843
26. Unger R.H. Lipotoxic diseases. Annu Rev Med 53 (2002) 319-336
27. Fishbein M.H., Miner M., Mogren C., et al. The spectrum of fatty liver in obese children and the relationship of serum aminotransferases to severity of steatosis. J Pediatr Gastroenterol Nutr 36 (2003) 54-61
28. Daniel S., Ben Menachem T., Vasudevan G., et al. Prospective evaluation of unexplained chronic liver transaminase abnormalities in asymptomatic and symptomatic patients. Am J Gastroenterol 94 (1999) 3010-3014